CHMP recommends approval for Averoa’s Xoanacyl, an oral therapy for chronic kidney disease: Grenoble, France Friday, April 4, 2025, 12:00 Hrs [IST] Averoa, a biopharmaceutical c ...

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic ren ...

Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a ...

Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, today announces a positive opinion from the European Medicines Agency (EMA)’s Committee for ...

The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three ...

Akebia Therapeutics, Inc.’s AKBA share price has dipped by 28.17%, which has investors questioning if this is right time to buy.

A “Strong Buy” rating from Wall Street indicates that analysts believe a stock has the potential for future price ...

Ala Ebtekar’s new cyanotypes for Arion Press were exposed using moon and starlight during a partial lunar eclipse ...